HSPC/Chol/DSPE-mPEG2000 (50/45/5, mol/mol) Liposomes
1200 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - PP-0005-10ML
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 10mL
Parameters
| Additional information | PBS, pH 7.4 |
|---|
PP-0005-10ML
HSPC/Chol/DSPE-mPEG2000 (50/45/5, mol/mol) Liposomes
HSPC/Chol/DSPE-mPEG2000 (50/45/5, mol/mol) Liposomes, 30 mM, extruded and supplied sterile-filtered in glass vial.
1200 €
PP-0005-2ML
HSPC/Chol/DSPE-mPEG2000 (50/45/5, mol/mol) Liposomes
HSPC/Chol/DSPE-mPEG2000 (50/45/5, mol/mol) Liposomes, 30 mM, extruded and supplied sterile-filtered in glass vial.
450 €
PP-0007-10ML
HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol) Liposomes
HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol) liposomes, 30 mM, extruded and supplied sterile-filtered in glass vial. PEGylated to improve stability, prolong circulation time and reduce reticuloendothelial system clearance for in vivo applications. The lipid composition of these liposomes is essentially identical to that of the well-characterized Doxil® formulation, and the liposomes are useful as a vehicle control for drug-loaded liposomes of the same composition.
1200 €
DLL-0018-A1-10ML
SP600125 Liposomes, Formulation HZ12
PEGylated liposomes containing JNK inhibitor SP600125 (Nsc75890). SP600125 is a reversible, ATP-competitive broad-spectrum JNK inhibitor (JNK1/JNK2, IC50 40 nM; JNK3, IC50 90 nM). with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA. SP600125 inhibits ferroptosis, autophagy, and activates apoptosis. SP600125 is insoluble in aqueous media. This product is a pre-formulated liposomal version of Sp600125 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
2995 €
DLL-0019-1A-10MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1995 €
DLL-0019-1A-25MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3295 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025